Conversely, the ADC brentuximab vedotin (BV), comprising a humanized IgG1 anti-CD30 monoclonal antibody conjugated to the antimitotic agent MMAE via a cleavable linker, demonstrated significant efficacy in CD30-positive lymphomas [107]. The gene discussed is TNFRSF8; the disease is lymphoma.